PROTAGONIST THERAPEUTICS INC (PTGX) Stock Overview
USA - NASDAQ:PTGX - US74366E1029 - Common Stock
PTGX Key Statistics, Chart & Performance
The current stock price of PTGX is 87 USD. In the past month the price increased by 47.81%. In the past year, price increased by 92.99%.
PTGX Latest News, Press Relases and Analysis
PTGX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.77 | 407.19B | ||
| AMGN | AMGEN INC | 13.3 | 156.19B | ||
| GILD | GILEAD SCIENCES INC | 15.14 | 145.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.07 | 104.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.37 | 59.85B | ||
| ARGX | ARGENX SE - ADR | 85.97 | 48.77B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.17 | 35.16B | ||
| INSM | INSMED INC | N/A | 34.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.54B | ||
| NTRA | NATERA INC | N/A | 23.23B | ||
| BIIB | BIOGEN INC | 9.15 | 21.49B |
Related stock screener links
About PTGX
Company Profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 130 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Company Info
PROTAGONIST THERAPEUTICS INC
7707 Gateway Blvd Ste 140
Newark California CALIFORNIA 94560 US
CEO: Dinesh V. Patel
Employees: 126
Phone: 15104740170
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
What is the stock price of PROTAGONIST THERAPEUTICS INC today?
The current stock price of PTGX is 87 USD. The price increased by 29.77% in the last trading session.
What is the ticker symbol for PROTAGONIST THERAPEUTICS INC stock?
The exchange symbol of PROTAGONIST THERAPEUTICS INC is PTGX and it is listed on the Nasdaq exchange.
On which exchange is PTGX stock listed?
PTGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROTAGONIST THERAPEUTICS INC stock?
19 analysts have analysed PTGX and the average price target is 71.49 USD. This implies a price decrease of -17.82% is expected in the next year compared to the current price of 87. Check the PROTAGONIST THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROTAGONIST THERAPEUTICS INC worth?
PROTAGONIST THERAPEUTICS INC (PTGX) has a market capitalization of 5.41B USD. This makes PTGX a Mid Cap stock.
How many employees does PROTAGONIST THERAPEUTICS INC have?
PROTAGONIST THERAPEUTICS INC (PTGX) currently has 126 employees.
What are the support and resistance levels for PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a support level at 62.97. Check the full technical report for a detailed analysis of PTGX support and resistance levels.
Is PROTAGONIST THERAPEUTICS INC (PTGX) expected to grow?
The Revenue of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -85.52% in the next year. Check the estimates tab for more information on the PTGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROTAGONIST THERAPEUTICS INC (PTGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PTGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PTGX, evaluating the profitability, health, valuation and growth aspects
- PROTAGONIST THERAPEUTICS INC (PTGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROTAGONIST THERAPEUTICS INC (PTGX) Sales and EPS estimates to see what analysts future expectations are.
- PROTAGONIST THERAPEUTICS INC (PTGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROTAGONIST THERAPEUTICS INC (PTGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROTAGONIST THERAPEUTICS INC (PTGX) Stock Chart to make your own analysis
- PROTAGONIST THERAPEUTICS INC (PTGX) Latest news and press-releases to stay up to date.
Does PROTAGONIST THERAPEUTICS INC (PTGX) stock pay dividends?
PTGX does not pay a dividend.
When does PROTAGONIST THERAPEUTICS INC (PTGX) report earnings?
PROTAGONIST THERAPEUTICS INC (PTGX) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of PROTAGONIST THERAPEUTICS INC (PTGX)?
The PE ratio for PROTAGONIST THERAPEUTICS INC (PTGX) is 124.29. This is based on the reported non-GAAP earnings per share of 0.7 and the current share price of 87 USD. Check the full fundamental report for a full analysis of the valuation metrics for PTGX.
What is the Short Interest ratio of PROTAGONIST THERAPEUTICS INC (PTGX) stock?
The outstanding short interest for PROTAGONIST THERAPEUTICS INC (PTGX) is 11.02% of its float. Check the ownership tab for more information on the PTGX short interest.
PTGX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PTGX. When comparing the yearly performance of all stocks, PTGX is one of the better performing stocks in the market, outperforming 95.01% of all stocks.
PTGX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to PTGX. While PTGX has a great health rating, its profitability is only average at the moment.
PTGX Financial Highlights
Over the last trailing twelve months PTGX reported a non-GAAP Earnings per Share(EPS) of 0.7. The EPS decreased by -73.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.88% | ||
| ROA | 7.25% | ||
| ROE | 7.79% | ||
| Debt/Equity | 0 |
PTGX Forecast & Estimates
19 analysts have analysed PTGX and the average price target is 71.49 USD. This implies a price decrease of -17.82% is expected in the next year compared to the current price of 87.
For the next year, analysts expect an EPS growth of -148.64% and a revenue growth -85.52% for PTGX